Parkinson Disease
Conditions
Keywords
Adoption, Opicapone, Motor fluctuations
Brief summary
This is a randomized, parallel group, multicentre, multinational, prospective, open-label exploratory study in Parkinson's disease (PD) patients to evaluate the add-on efficacy of opicapone 50 mg or an extra dose of levodopa (L-DOPA) 100 mg as first strategy for the treatment of wearing-off.
Detailed description
The study consists of a one-week screening period, four weeks of open-label treatment and two weeks of post-study follow-up. The total study duration for each patient will be approximately 7 weeks
Interventions
DRUGOpicapone
50 mg hard capsules. Oral administration, once-daily at bedtime, at least 1 hour before or after L-DOPA/carbidopa or benserazide (L-DOPA/DDCI).
DRUGL-DOPA/DDCI
L-DOPA/carbidopa or benserazide (L-DOPA/DDCI), 100/25 mg, oral administration
Sponsors
Bial - Portela C S.A.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
30 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Able to comprehend and willing to sign an informed consent form and to comply with all aspects of the study. 2. Male or female patients aged 30 years or older. 3. Diagnosed with idiopathic PD according to the UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria (2006) or according to the Movement Disorder Society (MDS) Clinical Diagnostic Criteria (2015). 4. Disease severity Stages I-III (Hoehn & Yahr staging) at ON. 5. Treated on a stable regimen for at least four weeks before screening with immediate-release L-DOPA/DDCI, three to four intakes per day, and up to maximum daily dose of 600 mg L-DOPA. 6. In case of any other anti-PD-treatments, they should be on a stable regimen for at least four weeks before screening, and not likely to need any adjustment during the study. 7. Signs of wearing-off phenomenon with average total daily OFF-time while awake of at least 1 hour, including the early morning pre-first dose OFF (i.e. the time between wake-up and response to the first L DOPA/DDCI dosage), despite optimal anti-PD therapy (based on Investigator's assessment). 8. Experiencing wearing-off phenomenon for at least 4 weeks but less than 2 years prior to screening. 9. For females: Postmenopausal for at least 2 years before screening, surgically sterile for at least 6 months before screening, or practicing effective contraception until the post-study visit. Female patients who request to continue with oral contraceptives must be willing to use non-hormonal methods of contraception in addition during the course of this study. 10. Have filled-in self-rating diary charts in accordance with the diary chart instructions and with ≤3 errors per day while awake, in the three consecutive days preceding randomization. 11. With at least 1 hour at OFF state per day, including the early morning pre-first dose OFF period (i.e. the time between wake-up and response to the first L DOPA/DDCI dosage), as recorded in at least two of the three-day self-rating diary charts for the three days preceding randomization. 12. Adequate compliance to relevant concomitant medication during the period between V1 and V2 (based on the Investigator's judgment).
Exclusion criteria
1. Non-idiopathic PD (atypical parkinsonism, secondary \[acquired or symptomatic\] parkinsonism, Parkinson-plus syndrome). 2. Severe and/or unpredictable OFF periods, according to Investigator's judgment. 3. Average total daily OFF-time while awake of \>5 hours, including the early morning pre-first dose OFF, despite optimal anti-PD therapy (based on Investigator's assessment). 4. Treatment with prohibited medication: entacapone, tolcapone, monoamine oxidase (MAO) inhibitors (except selegiline up to 10 mg/day in oral formulation or 1.25 mg/day in buccal absorption formulation, rasagiline up to 1 mg/day or safinamide up to 100 mg/day), apomorphine or antiemetics with antidopaminergic action (except domperidone) within the last 4 weeks before screening. 5. Previous or planned (during the entire study duration) deep brain stimulation or stereotactic surgery (e.g. pallidotomy, thalamotomy). 6. Previous or current use of opicapone or L-DOPA/carbidopa intestinal gel infusion. 7. Use of any other investigational product (IP), currently or within the 3 months (or within 5 half-lives of the IP, whichever is longer) before screening. 8. Past (within the past year) or present history of suicidal ideation or suicide attempts. 9. Current or previous (within the past year) alcohol or substance abuse excluding caffeine or nicotine. 10. Phaeochromocytoma, paraganglioma, or other catecholamine secreting neoplasms. 11. Known hypersensitivity to the excipients of IP (including lactose intolerance, galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption). 12. History of neuroleptic malignant syndrome or non-traumatic rhabdomyolysis. 13. History of severe hepatic impairment (Child-Pugh Class C). 14. Current or previous (within the past year) diagnosis of psychosis, severe major depression or other psychiatric disorders that, based on the Investigator's judgment, might place the patient at increased risk or interfere with assessments. 15. Any medical condition that might place the patient at increased risk or interfere with assessments. 16. For females: Pregnant or breastfeeding. 17. Employees of the Investigator, study centre, Sponsor, clinical research organisation and study consultants, when employees are directly involved in this study or other studies under the direction of this Investigator or study centre, and their family members. 18. Persons committed to an institution by virtue of an order issued either by the judicial or other authorities. 19. With an average total daily OFF-time while awake of \>5 hours, including the early morning pre-first dose OFF period (i.e. the time between wake-up and response to the first L DOPA/DDCI dosage), as recorded in at least two of the three-day self-rating diary charts for the three days preceding randomization
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Absolute OFF-time from baseline to end of study | up to 7 weeks | OFF = Time when medication has worn off and is no longer providing benefit with regard to mobility, slowness, and stiffness. |
| Proportion of patients with one hour or more reduction in Absolute OFF-time from baseline to end of study (OFF-time responders) | up to 7 weeks | OFF = Time when medication has worn off and is no longer providing benefit with regard to mobility, slowness, and stiffness. |
| Change in Absolute ON-time from baseline to end of study | up to 7 weeks | ON = Time when medication is providing benefit with regard to mobility, slowness, and stiffness. |
| Proportion of patients with one hour or more increase in Absolute ON-time from baseline to end of study (ON-time responders) | up to 7 weeks | ON = Time when medication is providing benefit with regard to mobility, slowness, and stiffness. |
| Change in Percentage OFF-time between baseline and end of study | up to 7 weeks | OFF = Time when medication has worn off and is no longer providing benefit with regard |
| Change in Percentage ON-time between baseline and end of study | up to 7 weeks | ON = Time when medication is providing benefit with regard to mobility, slowness, and stiffness. |
Countries
Germany, Italy, Portugal, Spain, United Kingdom
Outcome results
None listed